Healthcare Stock Insights: Peregrine Pharma Explodes, J&J and the FDA
DaVita (NYSE:DVA) acquires private equity HealthCare Partners for approximately $4.42 billion in cash and stock. The latter is theUnited States’ largest operator of medical groups and physician networks.
Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) explode following word of positive top-line results from a Phase IIb trial of its bavituximab lung cancer treatment. The results exhibited the doubling of overall response rates and an improvement in progression-free survival in patients who received the treatment.
An FDA review reports that Johnson & Johnson’s (NYSE:JNJ) blood thinner Xarelto appears to reduce the risk of new heart attacks and strokes in people with cardiac problems, although missing data ignites doubts as to whether the treatment actually works. An FDA advisory panel will vote on Wednesday on recommendation of the drug.
Achillion (NASDAQ:ACHN) shares move higher on Monday, perhaps due to the release of positive results from a Phase Ib trial of ACH-2684 for the Treatment of Hepatitis C. The FDA has already fast-tracked the firm’s ACH-3102, which is also for Hepatitis C.
Shares of Merck (NYSE:MRK) move down, after the nightmarish news that its follow-up evaluation of an AIDS vaccine trial that had to be stopped early has confirmed the worst fears of researchers: The drug made it more likely, and not less, that some men would become infected with H.I.V.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.